Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioconNSE:BIOCON -0.62%87 Pretax Margin % is 5.52% as of Mar. 2026, which is 60% below its 10-year median of 13.89. GuruFocus rates NSE:BIOCON with a GF Score™ of 87/100 and a GF Value™ of ₹339.52 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 941 Biotechnology companies, Biocon ranks better than 73.75% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Biocon's Pre-Tax Income for the
three
months ended in Mar. 2026 was ₹2,475 Mil. Biocon's Revenue for the
three
months ended in Mar. 2026 was ₹44,843 Mil. Therefore, Biocon's pretax margin for the quarter that ended in Mar. 2026 was 5.52%.
The historical rank and industry rank for Biocon's Pretax Margin % or its related term are showing as below:
NSE:BIOCON'
s Pretax Margin % Range Over the Past 10 Years
Min: 2.66 Med: 13.89 Max: 22.58
Current: 2.66
NSE:BIOCON's Pretax Margin % is ranked better than 73.75% of 941
companies
in the Biotechnology industry
Industry Median: -89.42
vs NSE:BIOCON: 2.66
Biocon (NSE:BIOCON) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Biocon Pretax Margin % Related Terms
Biocon Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Biocon's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BIOCON vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Biocon's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocon Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biocon's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Biocon's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocon (NSE:BIOCON) has a Pretax Margin % of 5.52% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Biocon and its competitors. This is 60% below median its historical median of 13.89. Over the past decade, Biocon's Pretax Margin % has ranged from 2.66 to 22.58. According to the industry distribution chart, Biocon ranks #247 out of 941 companies in the Biotechnology industry, placing it in the top 26.2%.
Is Biocon's Pretax Margin % too high?
Biocon's current Pretax Margin % of 5.52% is 60% below median its 10-year median of 13.89. Over the past 10 years, this metric has ranged from a low of 2.66 to a high of 22.58. Based on the distribution chart, Biocon ranks #247 out of 941 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biocon has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocon's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocon ranks #247 out of 941 companies for Pretax Margin %. This puts Biocon in the upper half of its industry. Historically, Biocon's own Pretax Margin % has ranged from 2.66 to 22.58 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Biocon and its competitors. Biocon's current Pretax Margin % is 5.52%, which is 60% below median its own 10-year median of 13.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocon stock overvalued right now?
Based on GuruFocus' analysis, Biocon (NSE:BIOCON) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹339.52, compared to a current price of ₹434.60 — trading 28% above its estimated fair value. The current Pretax Margin % is 5.52%, which is 60% below median its 10-year median of 13.89. Biocon's overall GF Score™ is 87/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Biocon (NSE:BIOCON), the current Pretax Margin % is 5.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocon (NSE:BIOCON) Overvalued in 2026?
Based on GuruFocus' analysis, Biocon stock appears to be overvalued.
The current stock price of ₹434.60 is trading 28% above its estimated GF Value™ of ₹339.52.
GuruFocus considers Biocon to be Modestly Overvalued.
Key valuation signals for NSE:BIOCON:
Pretax Margin %: 5.52% (60% below median its 10-year median of 13.89)
GF Value™: ₹339.52 vs. price of ₹434.60 (28% above fair value)
No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
87GF Score
Get the complete analysis for NSE:BIOCON
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOCON has been successfully added to your 
